MACK : Summary for Merrimack Pharmaceuticals, Inc. - Yahoo Finance

U.S. Markets closed

Merrimack Pharmaceuticals, Inc. (MACK)


NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
3.01-0.01 (-0.33%)
At close: 4:00PM EDT
People also watch
FOLDACHNSGYPCLDXHALO
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close3.02
Open3.03
Bid2.90 x 500
Ask3.01 x 5200
Day's Range2.96 - 3.06
52 Week Range2.83 - 9.02
Volume2,048,224
Avg. Volume3,411,114
Market Cap393.02M
Beta2.48
PE Ratio (TTM)-2.49
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Merrimack (MACK) Starts Enrollment in Solid Tumors Study
    Zacks2 days ago

    Merrimack (MACK) Starts Enrollment in Solid Tumors Study

    Merrimack Pharmaceuticals, Inc. (MACK) announced that it has enrolled the first patient in a phase I study on MM-310 for solid tumors.

  • American City Business Journals3 days ago

    ​Merrimack asset sale prompts legal blowback

    Cambridge-based Merrimack Pharmaceuticals has been hit with multiple lawsuits in the wake of a major overhaul that includes the sale of its top drug to a French company, according to a federal filing. Merrimack (MACK) announced in January that it was selling its pancreatic cancer drug Onivyde, along with a generic version of ovarian cancer drug Doxil, to Paris-based Ipsen for $575 million. Merrimack also said it was cutting its headcount from more than 400 to 80, while refocusing on a handful of early-stage drugs in its pipeline.

  • PR Newswire3 days ago

    Merrimack Initiates Phase 1 Study of MM-310 in Solid Tumors

    CAMBRIDGE, Mass., March 23, 2017 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (MACK) today announced the enrollment of its first patient in a Phase 1 study of MM-310 in solid tumors. "The initiation of this study is an important step in evaluating MM-310's safety and preliminary activity in patients diagnosed with solid tumors," said Vasileios Askoxylakis, MD, PhD, Medical Director and MM-310 Project Leader at Merrimack.